Novavax Inc (STU:NVV1)
€ 13.352 1.6 (13.61%) Market Cap: 1.95 Bil Enterprise Value: 1.72 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 72/100

Novavax Inc NVX-CoV2373 Clinical Update Call Transcript

Jun 14, 2021 / 12:30PM GMT
Release Date Price: €172.22 (+2.13%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Novavax PREVENT-19 Phase III Final Data Announcement Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker today, Silvia Taylor. You may begin.

Silvia Taylor
Novavax, Inc. - SVP of IR & Corporate Affairs

Good morning, and thank you to everyone who has joined today's call to discuss our PREVENT-19 Phase III final data results. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today. Please also note that we have posted the slides that we are using during this morning's call at novavax.com/events.

Joining me today for discussion and a Q&A period are Stan Erck, President and CEO; Dr. Gregory Glenn, President of Research and Development; Dr. Filip Dubovsky, EVP and Chief Medical Officer; and John Trizzino, EVP, Chief Commercial Officer,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot